<DOC>
	<DOCNO>NCT02864407</DOCNO>
	<brief_summary>To monitor safety profile effectiveness Vahelva Respimat Korean patient COPD routine clinical practice set</brief_summary>
	<brief_title>Vahelva Respimat Regulatory Post-marketing Surveillance Korean Patients With Chronic Obstructive Pulmonary Disease</brief_title>
	<detailed_description>Study Design : regulatory PMS study</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Olodaterol</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>Inclusion criterion : Patients start Vahelva Respimat accordance approve label Korea Age &gt; = 18 year enrolment Patients sign data release consent form Exclusion criterion : Patients hypersensitivity Vahelva Respimat excipients . Patients history hypersensitivity atropine derivative ( e.g . ipratropium , oxitropium , glycopyrronium , clidinium , umeclidinium ) Patients asthma Current participation clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>